Laser Immunotherapy: A Potential Treatment Modality for Keratinocyte Carcinoma

The role of the immune system in cancer growth is well recognized and the development of immunotherapy represents a breakthrough in cancer treatment. Recently, the use of systemic immunotherapy was extended to keratinocyte carcinoma (KC), specifically locally advanced and metastasizing basal and squ...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Silje Haukali Omland, Emily Cathrine Wenande, Inge Marie Svane, Joshua Tam, Uffe Høgh Olesen, Merete Hædersdal
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	keratinocyte carcinoma basal cell carcinoma (BCC) squamous cell carcinoma (SCC) laser immunotherapy laser immunotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/1fa94c013b4140299c70fa1b5d9749b0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1fa94c013b4140299c70fa1b5d9749b0
record_format	dspace
spelling	oai:doaj.org-article:1fa94c013b4140299c70fa1b5d9749b02021-11-11T15:30:25ZLaser Immunotherapy: A Potential Treatment Modality for Keratinocyte Carcinoma10.3390/cancers132154052072-6694https://doaj.org/article/1fa94c013b4140299c70fa1b5d9749b02021-10-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/21/5405https://doaj.org/toc/2072-6694The role of the immune system in cancer growth is well recognized and the development of immunotherapy represents a breakthrough in cancer treatment. Recently, the use of systemic immunotherapy was extended to keratinocyte carcinoma (KC), specifically locally advanced and metastasizing basal and squamous cell carcinoma. However, since most KC lesions are non-aggressive, systemic treatment with associated side effects is rarely justified. Conversely, topical immunotherapy with imiquimod remains restricted to premalignant and superficial lesions. Use of laser in the treatment of KC has evolved from physical tumor destruction and laser-assisted drug delivery to laser-mediated immune modulation. Evidence indicates that laser monotherapy can lead to immune cell infiltration, tumor reduction and resistance to tumor re-inoculation. Combining laser with immunotherapeutic agents, termed laser immunotherapy (LIT), may further potentiate immune activation and tumor response. Studies on LIT show not only direct anti-tumor effects but systemic adaptive immunity, illustrated by the prevention of tumor recurrence and regression in distant untreated tumors. These findings imply a therapeutic potential for both local and metastatic disease. This work provides rationales for immune-based treatment of KC and presents the current status of KC immunotherapy. Aiming to expand the field of KC immunotherapy, the review discusses the literature on immune activation following laser monotherapy and LIT.Silje Haukali OmlandEmily Cathrine WenandeInge Marie SvaneJoshua TamUffe Høgh OlesenMerete HædersdalMDPI AGarticlekeratinocyte carcinomabasal cell carcinoma (BCC)squamous cell carcinoma (SCC)laser immunotherapylaserimmunotherapyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5405, p 5405 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	keratinocyte carcinoma basal cell carcinoma (BCC) squamous cell carcinoma (SCC) laser immunotherapy laser immunotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	keratinocyte carcinoma basal cell carcinoma (BCC) squamous cell carcinoma (SCC) laser immunotherapy laser immunotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Silje Haukali Omland Emily Cathrine Wenande Inge Marie Svane Joshua Tam Uffe Høgh Olesen Merete Hædersdal Laser Immunotherapy: A Potential Treatment Modality for Keratinocyte Carcinoma
description	The role of the immune system in cancer growth is well recognized and the development of immunotherapy represents a breakthrough in cancer treatment. Recently, the use of systemic immunotherapy was extended to keratinocyte carcinoma (KC), specifically locally advanced and metastasizing basal and squamous cell carcinoma. However, since most KC lesions are non-aggressive, systemic treatment with associated side effects is rarely justified. Conversely, topical immunotherapy with imiquimod remains restricted to premalignant and superficial lesions. Use of laser in the treatment of KC has evolved from physical tumor destruction and laser-assisted drug delivery to laser-mediated immune modulation. Evidence indicates that laser monotherapy can lead to immune cell infiltration, tumor reduction and resistance to tumor re-inoculation. Combining laser with immunotherapeutic agents, termed laser immunotherapy (LIT), may further potentiate immune activation and tumor response. Studies on LIT show not only direct anti-tumor effects but systemic adaptive immunity, illustrated by the prevention of tumor recurrence and regression in distant untreated tumors. These findings imply a therapeutic potential for both local and metastatic disease. This work provides rationales for immune-based treatment of KC and presents the current status of KC immunotherapy. Aiming to expand the field of KC immunotherapy, the review discusses the literature on immune activation following laser monotherapy and LIT.
format	article
author	Silje Haukali Omland Emily Cathrine Wenande Inge Marie Svane Joshua Tam Uffe Høgh Olesen Merete Hædersdal
author_facet	Silje Haukali Omland Emily Cathrine Wenande Inge Marie Svane Joshua Tam Uffe Høgh Olesen Merete Hædersdal
author_sort	Silje Haukali Omland
title	Laser Immunotherapy: A Potential Treatment Modality for Keratinocyte Carcinoma
title_short	Laser Immunotherapy: A Potential Treatment Modality for Keratinocyte Carcinoma
title_full	Laser Immunotherapy: A Potential Treatment Modality for Keratinocyte Carcinoma
title_fullStr	Laser Immunotherapy: A Potential Treatment Modality for Keratinocyte Carcinoma
title_full_unstemmed	Laser Immunotherapy: A Potential Treatment Modality for Keratinocyte Carcinoma
title_sort	laser immunotherapy: a potential treatment modality for keratinocyte carcinoma
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/1fa94c013b4140299c70fa1b5d9749b0
work_keys_str_mv	AT siljehaukaliomland laserimmunotherapyapotentialtreatmentmodalityforkeratinocytecarcinoma AT emilycathrinewenande laserimmunotherapyapotentialtreatmentmodalityforkeratinocytecarcinoma AT ingemariesvane laserimmunotherapyapotentialtreatmentmodalityforkeratinocytecarcinoma AT joshuatam laserimmunotherapyapotentialtreatmentmodalityforkeratinocytecarcinoma AT uffehøgholesen laserimmunotherapyapotentialtreatmentmodalityforkeratinocytecarcinoma AT meretehædersdal laserimmunotherapyapotentialtreatmentmodalityforkeratinocytecarcinoma
_version_	1718435227127250944

Laser Immunotherapy: A Potential Treatment Modality for Keratinocyte Carcinoma

Ejemplares similares